These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7008102)

  • 1. [Bioavailability of 2 different rifampicin preparations].
    Aronne Benach MT; Naranjo Cascante G
    Rev Clin Esp; 1980 Oct; 159(1):43-6. PubMed ID: 7008102
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rifampicin and its clinical use].
    Fafrowicz B
    Wiad Lek; 1971 Jul; 24(3):233-8. PubMed ID: 4926926
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum rifampicin level in children with tuberculosis and in young mice].
    Zwolska-Kwiek Z; Ceglecka-Tomaszewska K; Ziółkowski J
    Pneumonol Pol; 1982 Nov; 50(11):571-9. PubMed ID: 6985082
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rifampicin preparations for internal use and their bioavailability].
    Zak AF; Batuashvili TA; Shchedrin VI
    Antibiotiki; 1981 Oct; 26(10):728-31. PubMed ID: 7305309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local diffusibility of rifampicin in tuberculous lesions of bone and joint.
    Popescu E; Algeorge G; Paunescu E; Stoinescu M; Rudescu D
    Respiration; 1971; 28():Suppl:44-51. PubMed ID: 5150795
    [No Abstract]   [Full Text] [Related]  

  • 7. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability.
    Brechbühler S; Fluehler H; Riess W; Theobald W
    Arzneimittelforschung; 1978; 28(3):480-3. PubMed ID: 580761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sex-related differences in the level of rifampicin in humans and animals].
    Zwolska-Kwiek Z
    Pneumonol Pol; 1982 Nov; 50(11):563-9. PubMed ID: 7182813
    [No Abstract]   [Full Text] [Related]  

  • 9. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of rifampicin in experimental animals and in man].
    Curci G; Ninni A
    Lotta Tuberc; 1971; 41(3):354-66. PubMed ID: 5291093
    [No Abstract]   [Full Text] [Related]  

  • 11. [Absorption, distribution, metabolism and excretion of rifampicin (3-(4-methyl-1-piperazinyl-iminomethyl) rifamycin SV) in the rat].
    Akimoto T; Ono K; Nanpo T
    Jpn J Antibiot; 1970 Jun; 23(3):250-6. PubMed ID: 5312377
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and pharmacokinetics of the antibiotic rifampin.
    Kenny MT; Strates B
    Drug Metab Rev; 1981; 12(1):159-218. PubMed ID: 7028436
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of meals on rifampicin absorption.
    Siegler DI; Bryant M; Burley DM; Citron KM; Standen SM
    Lancet; 1974 Jul; 2(7874):197-8. PubMed ID: 4135611
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man.
    Furesz S; Scotti R; Pallanza R; Mapelli E
    Arzneimittelforschung; 1967 May; 17(5):534-7. PubMed ID: 5631581
    [No Abstract]   [Full Text] [Related]  

  • 16. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of rifampin from various preparations and pharmaceutic forms.
    Männistö P
    Clin Pharmacol Ther; 1977 Mar; 21(3):370-4. PubMed ID: 319939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.
    van Crevel R; Nelwan RH; Borst F; Sahiratmadja E; Cox J; van der Meij W; de Graaff M; Alisjahbana B; de Lange WC; Burger D
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):500-3. PubMed ID: 15141745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels.
    Wardell WM; McQueen EG
    N Z Med J; 1970 Dec; 72(463):393-6. PubMed ID: 5278257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.